Recent Advance on Bone Targeting Drug Delivery System

doi:10.3969/j.issn.1005-4979.2017.01.012

Abstract

Abstract: Osteoporosis(OP) is a systemic bone metabolism disorder with damage of microstructures and high risks of fracture. Drugs for OP treatment, including biphosphonate and injection of PTH, may cause severe side effect due to lacking of bone specific ability. The main idea of devoleping new drugs for osteoporosis is to deliver drugs to bone or target cells specificly. Bone targeting delivery system could reduce side effect by selectively delivering drugs to bone or bone specific cells. This article is intended to summarize the development of bone targeting drug delivery sysytem.

Key words: osteoporosis, bone targeting drug delivery system, bone targeting peptide

摘要： 骨质疏松症是一种由骨量减少、骨骼微细结构发生破坏所导致骨骼脆弱而易骨折的系统性疾病。常用的治疗方式包括口服或注射双膦酸盐、甲状旁腺素等。由于骨质疏松症的特殊局部环境，导致常用给药方式存在用药频率高、用量大、毒副作用相对较强的缺点。因此如何将药物靶向输送到骨表面甚至靶细胞，是研发新药的重点。骨靶向药物递送系统能够将药物靶向递送至骨或骨特异性细胞，降低给药剂量，减少全身毒性。本文对目前骨靶向药物递送系统及其研究进展作一综述。

关键词: 骨质疏松症； , 骨靶向药物递送系统； , 多肽类靶头

CLC Number:

R782

CAI Ming-xiang, SUN Yao. Recent Advance on Bone Targeting Drug Delivery System[J]. 《Journal of Oral and Maxillofacial Surgery》, 2017, 27(1): 56-.

蔡明详（综述）孙瑶（审校）. 骨靶向药物递送系统的研究进展[J]. 《口腔颌面外科杂志》, 2017, 27(1): 56-.

/ / Recommend / Download Citations

URL: https://journal06.magtech.org.cn/Jweb_joms/EN/10.3969/j.issn.1005-4979.2017.01.012

https://journal06.magtech.org.cn/Jweb_joms/EN/Y2017/V27/I1/56

References

[1] Mauney J, Olsen BR, Volloch V. Matrix remodeling as stem cell recruitment event: a novel in vitro model for homing of human bone marrow stromal cells to the site of injury shows crucial role of extracellular collagen matrix [J]. Matrix Biol, 2010, 29(8):657-663.

[2] Gallo J, Raska M, Mrazek F, et al. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis [J]. Physiol Res, 2008, 57(3):339-349.

[3] Mundy GR. Pathogenesis of osteoporosis and challenges for drug delivery[J]. Adv Drug Deliv Rev, 2000, 42(3):165-173.

[4] Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate [J]. N Engl J Med, 2005, 353(6):566-575.

[5] Martin J, Shearer, Paul N.Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis [J]. J Lipid Res, 2014, 55(3):345-362.

[6] Kristensen SR, Abrahamsen B, Madsen JS, et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS) [J]. Thromb Haemost, 2006, 95(5):915-916.

[7] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [J]. N Engl J Med, 2001, 344(19):1434-1441.

[8] Sato T, Watanabe K, Masuhara M, et al. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro [J]. J Bone Miner Metab, 2007, 25(1):19-27.

[9] Mozzati M, Arata V, Gallesio G. Tooth extraction in osteoporotic patients taking oral bisphosphonates[J]. Osteoporos Int, 2013, 24(5):1707-1712.

[10] Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases [J]. J Cancer Res Clin Oncol, 2010, 136(8):1117-1124.

[11] Kobayashi Y, Ueyama S, Arai Y, et al. The active metabolite of leflunomide, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage [J]. J Bone Miner Metab, 2004, 22(4):318-328.

[12] Andersen TL, Soe K, Sondergaard TE, et al. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells [J]. Br J Haematol, 2010, 148(4):551-561.

[13] Liu X. Bone site-specific delivery of siRNA [J]. J Biomed Res, 2016, 30(4):264-271.

[14] Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents [J]. Clin Pharmacokinet, 2003, 42(15):1319-1330.

[15] Xinluan W, Yuxiao L, Helena NH, et al. Systemic drug delivery systems for bone tissue regeneration- a mini review [J]. Curr Pharm Des, 2015, 21(12):1575-1583.

[16] Hirabayashi H, Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS) [J]. J Control Release, 2001, 70(1-2):183-191.

[17] Wang D, Miller SC, Kopeckova P, et al. Bone-targeting macromolecular therapeutics[J]. Adv Drug Deliv Rev, 2005, 57(7):1049-1076.

[18] Li X, Tsibouklis J, Weng T, et al. Nano carriers for drug transport across the blood-brain barrier [J]. J Drug Target, 2016, 19(1):1-12.

[19] Marit G, Mark G. Papich, John T, Luca G. Pharmacodynamics of doxycycline and tetracycline against staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline [J]. J Clin Microbiol, 2013, 51(11): 3547-3554.

[20] Albert A, Rees CW. Avidity of the tetracyclines for the cations of metals [J]. Nature, 1956, 177(4505):433-434.

[21] Skinner HC, Nalbandian J. Tetracyclines and mineralized tissues: review and perspectives [J]. Yale J Biol Med, 1975, 48(5):377-397.

[22] Ibsen KH. Studies on the association of the tetracyclines with mineralized tissue[J]. Clin Orthop Relat Res, 1985,(200):85-86.

[23] Perrin DD. Binding of tetracyclines to bone [J]. Nature, 1965, 208(5012):787-788.

[24] Kinirons MJ. Reduction in evidence in children's teeth of use of tetracyclines [J]. Br Med J, 1983, 287(6404): 1515.

[25] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83 (9) :1032-1045.

[26] van beek E, Lowik C, van der Pluijm G, et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates [J]. J Bone Miner Res, 1999, 14(5):722-729.

[27] Wolf SM, Jones C. Designing oversight for nanomedicine research in human subjects: systematic analysis of exceptional oversight for emerging technologies [J]. J Nanopart Res, 2011, 13(4):1449-1465.

[28] Giger EV, Castagner B, Raikkonen J, et al. siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators[J]. Adv Healthc Mater, 2013, 2(1):134-144.

[29] Mundy GR, Chen D, Zhao M, et al. Growth regulatory factors and bone [J]. Rev Endocr Metab Disord, 2001, 2(1): 105-115.

[30] Mansukhani A, Bellosta P, Sahni M, et al. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts [J]. J Cell Biol, 2000, 149(6):1297-1308.

[31] Funahashi, Y. Current status of VEGF-targeted therapy and multiple-targeted receptor tyrosine kinase inhibitors targeting VEGF and FGF-receptors [J]. Nihon Yakurigaku Zasshi, 2010, 136(4):204-209.

[32] Liang C, Guo B, Wu H, et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy [J]. Nat Med, 2015, 21(3):288-294.

[33] Midura RJ, Wang A, Lovitch D, et al. Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures [J]. J Biol Chem, 2004, 279(24):25464-25473.

[34] Anai N, Kothari, Matthew L, et al. Osteopontin--a master regulator of epithelial-mesenchymal transition [J]. J Clin Med, 2016, 5(4):39.

[35] Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein [J]. Nature, 1997, 386(6620):78-81.

[36] Bennick A, Cannon M, Madapallimattam G. The nature of the hydroxyapatite-binding site in salivary acidic proline-rich proteins [J]. Biochem J, 1979, 183(1):115-126.

[37] Kasugai S, Fujisawa R, Waki Y, et al. Selective drug delivery system to bone: small peptide (Asp)6 conjugation [J]. J Bone Miner Res, 2000, 15(5):936-943.

[38] Yokogawa K,Toshima K,Yamoto K, et al. Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol [J]. Biol Pharm Bull, 2006, 29(6):1229-1233.

[39] Wang D, Miller S, Sima M, et al. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems [J]. Bioconjug Chem, 2003, 14(5):853-859.

[40] Zhu Q, Gibson MP, Liu Q, et al. Proteolytic processing of dentin sialophosphoprotein (DSPP) is essential to dentinogenesis [J]. J Biol Chem, 2012, 287(36):30426-30435.

[41] Cross KJ, Huq NL, Reynolds EC. Protein dynamics of bovine dentin phosphophoryn [J].J Pept Res 2005, 66(2): 59-67.

[42] Yarbrough DK, Hagerman E, Eckert R, et al. Specific binding and mineralization of calcified surfaces by small peptides [J]. Calcif Tissue Int, 2010, 86(1):58-66.

[43] Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy [J]. Nat Med, 2012, 18(2):307-314.

[44] Sun Y, Ye X, Cai MX, et al. Osteoblast-targeting-peptide modified nanoparticle for siRNA/microRNA delivery [J]. ACS Nano, 2016, 10(6):5759-5768.

Please choose a citation manager

Content to export